ZLD1039 (a selective EZH2 inhibitor) effectively inhibits the expression of EZH2 and H3K27me3, and blocked the upregulation of RKIP and activation of nuclear factor-κB (NF-κB) p65 signaling pathway, thus alleviating inflammation in cisplatin-induced AKI (Wen et al., 2021). The gene discussed is EZH2; the disease is acute kidney injury.